Lintuzumab

林妥珠单抗

Report date: 2022/08/29 20:00:24

Base Information

Drug NameLintuzumab
Drug Alias NameAnti-CD33 MAbHuM-195SGN-33
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunostimulantsMyeloid cell surface antigen CD33 inhibitorsCytokines inhibitors
TargetsCytokinesMyeloid cell surface antigen CD33
Therapy Area/IndicationsNeutropeniaMyelodysplastic SyndromesLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPdl Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen IncNational Cancer InstituteFacet Biotech Pvi Ltd
Active IndicationsN/A
Inactive IndicationsNeutropeniaMyelodysplastic SyndromesLeukemia

Other Information

ATC CodeN/A
Related LinksWikipedia